Patent Assignment Details
NOTE:Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.
|
| Reel/Frame: | 061083/0427 | |
| Pages: | 7 |
| | Recorded: | 08/10/2022 | | |
| Attorney Dkt #: | 200196-US-CNT |
| Conveyance: | CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 17123177 PREVIOUSLY RECORDED AT REEL: 055548 FRAME: 0389. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . |
|
|
Total properties:
1
|
|
|
|
Patent #:
|
NONE
|
Issue Dt:
|
|
Application #:
|
17123777
|
Filing Dt:
|
12/16/2020
|
|
Publication #:
|
|
Pub Dt:
|
06/17/2021
| | | | |
|
Title:
|
Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
|
|
|
Assignee
|
|
|
|
|
| SE-151 85 |
| SODERTALJE, SWEDEN |
|
|
Correspondence name and address
|
| |
ASTRAZENECA
|
| |
ONE MEDIMMUNE WAY
|
| |
GAITHERSBURG, MD 20878
|
Search Results as of:
06/28/2024 10:02 PM
If you have any comments or questions concerning the data displayed,
contact
PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified:
August 25, 2017 v.2.6
| 
